Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug‐eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy-Reference-Cited by-同舟云学术

Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug‐eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy

Published:2019-04-09 Issue:1 Volume:95 Page:89-96
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Catheter Cardiovasc Interv

Author:

Tijssen Ruben Y.G.¹,Schaaf Rene J.²,Kraak Robin P.¹²^ORCID,Vink Maarten A.²,Hofma Sjoerd H.³,Arkenbout E. Karin⁴,Weevers Auke P.J.D.⁵,Kerkmeijer Laura S.M.¹,Onuma Yoshinobu⁶,Serruys Patrick W.⁷^ORCID,Beijk Marcel A.M.¹,Koch Karel T.¹,Baan Jan¹,Vis M. Marije¹,Piek Jan J.¹^ORCID,Tijssen Jan G.P.¹,Henriques Jose P.S.¹,Winter Robbert J.¹,Wykrzykowska Joanna J.¹

Affiliation:

1. Amsterdam UMC, University of AmsterdamHeart Center, Academic Medical Center Amsterdam The Netherlands

2. The Department of CardiologyOnze Lieve Vrouwe Gasthuis Amsterdam The Netherlands

3. The Department of CardiologyMedical Center Leeuwarden Leeuwarden The Netherlands

4. The Department of CardiologyTergooi Hospital Blaricum The Netherlands

5. The Department of CardiologyAlbert Schweitzer Hospital Dordrecht The Netherlands

6. Thoraxcenter, Erasmus MC Rotterdam The Netherlands

7. NHLIImperial College London London United Kingdom

Funder

Abbott Vascular

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.28193

Reference19 articles.

1. 2018 ESC/EACTS Guidelines on myocardial revascularization

2. Pathology of Drug-Eluting Stents in Humans

3. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice

4. Quality difference of neointima following the implantation of everolimus‐eluting bioresorbable scaffolds and metallic stents in patients with ST‐elevation myocardial infarction: Quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial;Sotomi Y;EuroIntervention,2018

5. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial;EuroIntervention;2022-03

2. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome;Journal of Clinical Medicine;2021-07-18

3. Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold;Cardiovascular Intervention and Therapeutics;2021-01-02

4. Continuous Based Direct Ink Write for Tubular Cardiovascular Medical Devices;Polymers;2020-12-28